Ulrich Lücking
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ulrich Lücking has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Gerhard Siemeister
Corporate Research Oncology, Schering AG, 13342 Berlin, Germany
1 shared publicationHans Briem
CDCC/Computational Chemistry, Research Center Europe, Schering AG, 13342 Berlin, Germany
1 shared publicationMartin Krüger
Medicinal Chemistry, Research Center Europe, Schering AG, 13342 Berlin, Germany, Fax: (+49) 30-468-18170
1 shared publicationMartina Schäfer
ET/Structural Biology, Research Center Europe, Schering AG, 13342 Berlin, Germany
1 shared publicationPhilip Lienau
CDCC/Research Pharmacokinetics, Research Center Europe, Schering AG, 13342 Berlin, Germany
1 shared publicationRolf Jautelat
Medicinal Chemistry, Research Center Europe, Schering AG, 13342 Berlin, Germany, Fax: (+49) 30-468-18170
1 shared publication
Latest Publications
- 27 December 2006
- Published by Wiley in ChemMedChem
- Vol. 2 (1) , 63-77
Macrocyclic Aminopyrimidines as Multitarget CDK and VEGF‐R Inhibitors with Potent Antiproliferative Activities
X‐ray structures from CDK2–aminopyrimidine inhibitor complexes led to the idea to stabilize the active conformation of aminopyrimidine inhibitors by incorporating the recognition site into a macrocyclic framework. A modular synthesis approach that relies on a new late‐stage macrocyclization protocol that enables fast and efficient synthesis of macrocyclic aminopyrimidines was developed. A set of structurally diverse derivatives was prepared. Macrocyclic aminopyrimidines were shown to be multitarget inhibitors of CDK1/2 and VEGF‐RTKs. In addition, potent antiproliferative activities toward various human tumor cells and a human tumor xenograft model were demonstrated.
- 27 December 2006
- Published by Wiley in ChemMedChem
- Vol. 2 (1) , 63-77
Macrocyclic Aminopyrimidines as Multitarget CDK and VEGF‐R Inhibitors with Potent Antiproliferative Activities
X‐ray structures from CDK2–aminopyrimidine inhibitor complexes led to the idea to stabilize the active conformation of aminopyrimidine inhibitors by incorporating the recognition site into a macrocyclic framework. A modular synthesis approach that relies on a new late‐stage macrocyclization protocol that enables fast and efficient synthesis of macrocyclic aminopyrimidines was developed. A set of structurally diverse derivatives was prepared. Macrocyclic aminopyrimidines were shown to be multitarget inhibitors of CDK1/2 and VEGF‐RTKs. In addition, potent antiproliferative activities toward various human tumor cells and a human tumor xenograft model were demonstrated.